Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Filgotinib→

Filgotinib PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1206161-97-8
Molecular formula
C21H23N5O3S
Molecular weight
425.5 g/mol
Drug class
Preferential Janus kinase 1 (JAK1) inhibitortargeted synthetic immunomodulator
Mechanism of action
ATP-competitive and reversible inhibitor of the JAK family, with preferential inhibition of JAK1 over JAK2, JAK3 and TYK2. This reduces phosphorylation and activation of STAT transcription factors downstream of multiple inflammatory cytokine receptors.
Indications / reported uses
  • Treatment of moderate-to-severe active rheumatoid arthritis in adults with inadequate response or intolerance to one or more disease-modifying antirheumatic drugs; monotherapy or in combination with methotrexate
  • Treatment of moderately-to-severely active ulcerative colitis in adults after inadequate response, loss of response or intolerance to conventional or biological therapy; use is subject to product-specific warnings and eligibility restrictions

Sources: EMA EPAR — Jyseleca · EMA product information — Jyseleca · UK SmPC — Jyseleca 100 mg · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Preferential Janus kinase 1 (JAK1) inhibitor; targeted synthetic immunomodulator

Mechanism of action

ATP-competitive and reversible inhibitor of the JAK family, with preferential inhibition of JAK1 over JAK2, JAK3 and TYK2. This reduces phosphorylation and activation of STAT transcription factors downstream of multiple inflammatory cytokine receptors.

General use cases

  • Treatment of moderate-to-severe active rheumatoid arthritis in adults with inadequate response or intolerance to one or more disease-modifying antirheumatic drugs; monotherapy or in combination with methotrexate
  • Treatment of moderately-to-severely active ulcerative colitis in adults after inadequate response, loss of response or intolerance to conventional or biological therapy; use is subject to product-specific warnings and eligibility restrictions

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Filgotinib PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Filgotinib Permitted Daily Exposure (PDE) report (the Filgotinib PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Filgotinib Occupational Exposure Limit (OEL) report (the Filgotinib OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.